Trial reportClinical cardiology2019
Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation.
Trial report in Clinical cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Trial
- Effects of ezetimibe/simvastatin 10/10 mg versus Rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation.BMC cardiovascular disorders · 2019Trial
- Comparison of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation.Clinical cardiology · 2019Trial
- Review
- Fimasartan ameliorates renal ischemia reperfusion injury via modulation of oxidative stress, inflammatory and apoptotic cascades in a rat model.Journal of medicine and life · 2022Article
- Blood Pressure-Lowering Therapy.Handbook of experimental pharmacology · 2022Article
- Evolutionary medical insights into the SARS-CoV-2 pandemic.Evolution, medicine, and public health · 2020Article
- Fimasartan: A new armament to fight hypertension.Journal of family medicine and primary care · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe renin-angiotensin system plays an important role in promoting atherosclerotic plaque inflammation, which may be inhibited by angiotension-II receptor blockers. HYPOTHESIS: We investigated the effects of fimasartan and amlodipine therapy on carotid atherosclerotic plaque inflammation using
methodsFifty patients with acute coronary syndrome (ACS) and at least one lesion with
resultsThe two groups had similar baseline characteristics. At the 6-month follow-up, index vessel and aorta MDS TBR significantly decreased in both groups. However, the percent change in index vessel MDS TBR was similar between the two groups (-9.33 ± 14.2% vs -7.73 ± 19.1%, respectively, P = 0.9). No significant difference was found for the percent change in the whole vessel TBR for the index vessel between the two groups, with similar findings for changes in MDS TBR or whole vessel TBR for the aorta. Total cholesterol, low-density lipoprotein cholesterol levels, and blood pressure improved to a similar degree in both groups.
conclusionsFimasartan and amlodipine reduce carotid atherosclerotic plaque inflammation similarly in patients with ACS, offering the same level of effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.